Sarepta said it was halting shipments of its Duchenne gene therapy for patients who can no longer walk, following the death of a second recipient.

Sarepta Therapeutics (NASDAQ:SRPT) reported a second fatality from acute liver failure in a patient treated with its gene therapy, Elevidys, designed for Duchenne muscular dystrophy (DMD), Bloomberg News reported Sunday.

Retail investor chatter around Sarepta Therapeutics surged on Sunday after the company announced it had suspended shipments and paused a clinical trial of its gene therapy Elevidys for non-ambulatory patients with Duchenne muscular dystrophy following a second patient death from acute liver failure.